

Semel Grand Rounds

July 30, 2024 at 11:00 AM – 12:00 PM

Live In-Person/Live Virtual

Semel Grand Rounds - 7/30/2024 - Gitlin

Overview

The Semel Institute for Neuroscience and Human Behavior at UCLA is pleased to present Semel Grand Rounds, our weekly educational conference featuring presentations on evidence-based clinical practices, cutting-edge insights from neuroscience, and the role of society in shaping mental health.

Learning Objectives

- 1 Describe what clinicians can (and can't) do to address structural determinants of health and care
- 2 List the criteria for autoimmune psychosis as distinct from autoimmune encephalitis
- 3 Discuss what (social and affective) neuroscience itself has to say about inequality and bias, and how to counter it
- 4 Explain the role of synapse formation in mediating antidepressant effects and sustaining them over time
- 5 Discuss the impact of telehealth on mental health care quality

Target Audience

Specialties - Psychiatry And Neurology, Addiction Psychiatry, Child And Adolescent Psychiatry, Consultation-Liaison Psychiatry, Forensic Psychiatry, Geriatric Psychiatry, Neurocritical Care, Psychiatry

Professions - Physician, Non-Physician, Advanced Practice Nurse, Behavioral Therapist, Counselor, Fellow, Fellow/Resident, Marriage & Family Therapist, Medical Student, Nurse, Occupational Therapist, Physician Assistant, Psychologist, Resident, Social Worker

Accreditation Statement



The David Geffen School of Medicine at UCLA is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statements

The David Geffen School of Medicine at UCLA designates this live activity for a maximum of 1.00 AMA PRA Category 1 *Credit(s)*TM.Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement

The individuals below have been identified as having a position to influence the content of this educational activity. As such, they have disclosed the absence or presence of a relevant financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All of the relevant financial relationships for these individuals have been mitigated. Nature of Relationship(s) / Name of Ineligible Name of individual Individual's role in activity Company(s) Jonathan Heldt, Other Nothing to disclose - 11/30/2023 Course Director Nothing to disclose - 01/13/2024 ppolytos Kalofonos, PhD Other Planning Committee Member Sarah Nguyen, MD Other Planning Committee Member Nothing to disclose - 12/13/2023 Nothing to disclose - 12/15/2023 Jonathan Flint, MD Other Planning Committee Member Tara S Peris, PhD Other Planning Committee Member Nothing to disclose - 03/25/2024

Michael Gitlin, MD, Professor	Faculty, Other Planning Committee Member	Nothing to disclose - 01/16/2024
Jennifer Kruse, MD	Other Planning Committee Member	Nothing to disclose - 11/30/2023
Anna Kurtz, LCSW	Other Planning Committee Member	Nothing to disclose - 12/04/2023
Andrew Leuchter, MD	Other Planning Committee Member	Consulting Fee-NeoSync Consulting Fee- eFovea Consulting Fee-Options MD Grant or research support-Neuroptics Grant or research support-The Department of Defense Grant or research support-MagVenture Grant or research support-NIH - UCLA-CDU CFAR - 01/16/2024
Stephen 1 Marder, MD	Other Planning Committee Member	Consulting Fee-Merck (Any division) Merck (Any division) Consulting Fee-Karuna Consulting Fee- Sunovion Pharmaceuticals, Inc. Consulting Fee- Boehringer Ingelheim Pharmaceuticals, Inc. Consulting Fee-Roche (Any division) (Relationship has ended) - 12/20/2023
Margaret Stuber, MD, Distinguished Professor	Other Planning Committee Member	Nothing to disclose - 12/21/2023
Sue Ellen Zhang, Other	Activity Coordinator	Nothing to disclose - 01/17/2024
Keith Nuechterlein, PhD, Clinical Psychologist	Other Planning Committee Member	Grant or research support-Janssen (Any division) (Relationship has ended) Grant or research support-Boehringer Ingelheim Pharmaceuticals, Inc. Honoraria-Boehringer Ingelheim Pharmaceuticals, Inc. (Relationship has ended) Paid consultant-Recognify - 01/19/2024

Commercial Support This activity has not received commercial support.

Connect with Us Center for Continuing Medical Education (CCPD) <u>ccpd@mednet.ucla.edu</u> (310) 794-2620